| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$588 |
Appendix 4D and Half Year Report
|
26 Feb 2025 8:13AM |
$0.505 |
$0.300 |
fallen by
40.59%
|
|
BOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Botanix Pharmaceuticals is a clinical dermatology company marketing Sofdra, a treatment for primary axillary hyperhidrosis.
- The company reported a net loss of $30,888,119 for the half-year ended 31 December 2024.
- Sofdra was approved by the FDA on June 18, 2024, and initial prescriptions began in December 2024.
- Botanix incurred significant expenses in sales and marketing, totaling $8,862,001.
- The company expects Q1 2025 to be the first quarter of commercial revenue from Sofdra.
- Botanix has engaged 27 territory managers for the Sofdra launch and has completed sales training.
- The company has finalized terms with US commercial payers, making Sofdra accessible to 167 million lives.
- A successful Patient Experience Program provided insights for the broader product launch.
- The report indicates a material uncertainty regarding the company's ability to continue as a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReadyTech Holdings Limited (RDY) ORDINARY FULLY PAID |
Information Technology |
$281 |
Half Year Results - Media Release
|
26 Feb 2025 8:12AM |
$3.300 |
$2.300 |
fallen by
30.30%
|
|
RDY - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased 6.6% to $58.3 million for 1H FY25
- Recurring revenue represented 85.6% of total revenue
- Net revenue retention was 102%
- Underlying EBITDA grew by 4.6% to $18.2 million
- Strong contributions from Education and Workforce Solutions
- Enterprise pipeline exceeds $37.5 million
- Strategic contract wins include entry into the University market
- Investment in R&D and Sales & Marketing at 29% and 8.6% of revenue respectively
- Expectations for double-digit growth in key segments
- Focus on innovation and AI-enhanced solutions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,542 |
Update - Notification of buy-back - MGH
|
26 Feb 2025 8:12AM |
$3.560 |
$4.250 |
risen by
19.38%
|
|
| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$855 |
Dividend/Distribution - KLS
|
26 Feb 2025 8:12AM |
$3.620 |
$3.150 |
fallen by
12.98%
|
|
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$853 |
FY25 Half Year Results App4D and Interim Report
|
26 Feb 2025 8:12AM |
$2.860 |
$2.290 |
fallen by
19.93%
|
|
IDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 9.3% to $252.9 million.
- EBITDA rose 210.0% to $35.1 million.
- Net loss for the half-year was $396,000 compared to a loss of $66.8 million last year.
- A fully franked interim dividend of 2.5 cents per share was declared.
- The company completed the acquisition of Capitol Health Limited.
- Operating NPAT growth of 31.9% was reported before various costs.
- Strong free cash flow growth of 22.7% was achieved.
- Net debt to EBITDA ratio improved to 2.8x.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReadyTech Holdings Limited (RDY) ORDINARY FULLY PAID |
Information Technology |
$281 |
Appendix 4D and Interim Report
|
26 Feb 2025 8:12AM |
$3.300 |
$2.300 |
fallen by
30.30%
|
|
RDY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 6.6% to $58.3 million.
- Reported a loss after tax of $18.7 million.
- Strong contributions from Education, Workforce Solutions, and Justice segments.
- Net revenue retention at 102%.
- Recurring revenue represented 85.6% of total revenue.
- Acquisition of CouncilWise expected to enhance local government offerings.
- Underlying EBITDA margin remains stable at 31.2%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tyro Payments Limited (TYR) ORDINARY FULLY PAID |
Financials |
$462 |
Tyro Payments H1 FY25 ASX Release
|
26 Feb 2025 8:12AM |
$0.895 |
$0.875 |
fallen by
2.23%
|
|
TYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Gross profit grew 6.5% on H1 FY24 to $112.0 million.
- EBITDA grew 20.6% on H1 FY24 to $33.0 million.
- Net profit before tax doubled to $10.3 million.
- Strong free cash flow of $9.0 million.
- 34% growth in banking users.
- Tyro Health delivered 16.2% increase in transaction volume.
- Tyro reaffirms FY25 guidance of gross profit between $218 million and $226 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tyro Payments Limited (TYR) ORDINARY FULLY PAID |
Financials |
$462 |
Tyro Payments H1 FY25 Investor Presentation
|
26 Feb 2025 8:12AM |
$0.895 |
$0.875 |
fallen by
2.23%
|
|
TYR - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY25 results show strong growth with gross profit of $112 million.
- EBITDA increased by 20.6% compared to H1 FY24.
- On track to deliver FY25 guidance with gross profit expected to be between $218 million and $226 million.
- Improved operating efficiency with operating expenses being managed effectively.
- Tyro Health is expected to contribute significantly to gross profit from FY26.
- Positive trends in Tyro's banking proposition demonstrate value to merchants.
- Tyro is investing in technology to enhance customer experience and payment solutions.
- The firm reported a significant increase in active merchant accounts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Storage REIT (NSR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$3,381 |
NSR Half Year Results Presentation
|
26 Feb 2025 8:11AM |
$2.250 |
$2.430 |
risen by
8%
|
|
| Tyro Payments Limited (TYR) ORDINARY FULLY PAID |
Financials |
$462 |
Tyro Payments FY25 Interim Report
|
26 Feb 2025 8:11AM |
$0.895 |
$0.875 |
fallen by
2.23%
|
|
TYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Gross profit increased by 6.5% to $112.0 million.
- EBITDA rose by 20.6% to $33.0 million.
- Statutory profit before tax increased by 99.6% to $10.3 million.
- Active Tyro Bank Account users grew by 34% compared to the previous year.
- The company aims to provide integrated payments and banking solutions for SMEs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Storage REIT (NSR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$3,381 |
NSR Half Year Results Announcement
|
26 Feb 2025 8:11AM |
$2.250 |
$2.430 |
risen by
8%
|
|
| ImpediMed Limited (IPD) ORDINARY FULLY PAID |
Health Care |
$61 |
Appendix 4D and Interim Financial Report
|
26 Feb 2025 8:11AM |
$0.045 |
$0.030 |
fallen by
33.33%
|
|
IPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for half-year ended 31 December 2024 was $6.0 million.
- Revenue increased by $1.2 million or 26% compared to the prior period.
- Net loss for the period was $11.1 million, up from $9.7 million year-over-year.
- Operating expenses totaled $17.3 million, compared to $17.1 million in the prior corresponding period.
- ImpediMed focuses on bioimpedance spectroscopy technology for medical applications.
- A new growth capital facility of $15 million was secured for ongoing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$46 |
H1 FY2025 financial results
|
26 Feb 2025 8:11AM |
$0.099 |
$0.069 |
fallen by
30.30%
|
|
VIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of $62.7 million, up 4.5% from the previous year.
- Normalized EBITDA of $4.6 million, reflecting acquisition costs and legal dispute resolutions.
- Normalized profit after income tax down 42% to $2.2 million.
- New CEO Geoff Cockerill appointed and a strategy reset being implemented.
- Acquisition of Releaf Group assets providing access to 30,000 additional patients.
- Doctors on Demand telehealth business grew significantly with a 230% increase in revenue.
- Successful settlement of legacy legal disputes reducing operational risks.
- Acquisition of Candor Medical completed, adding 15,000 active patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$113 |
Update - Notification of buy-back - TOP
|
26 Feb 2025 8:10AM |
$0.630 |
$0.640 |
risen by
1.59%
|
|
| National Storage REIT (NSR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$3,381 |
Update - Dividend/Distribution - NSR
|
26 Feb 2025 8:10AM |
$2.250 |
$2.430 |
risen by
8%
|
|
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$1,003 |
2024 Full Year Investor Presentation
|
26 Feb 2025 8:10AM |
$7.870 |
$7.390 |
fallen by
6.10%
|
|
SIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $305.8m, up 22% v pcp
- Operating EBITDA of $118.7m, up 18% v pcp
- NPATA of $72.4m, up 15% v pcp
- 445,000 active customers at December 24, an increase of 12% v pcp
- 74,300 novated leases under management, an increase of 22% v pcp
- 20% growth in leasing settlements v pcp
- Record date of final and special dividend is 7 March 2025
- Customer engagement through new digital assets
- Improvement in customer experience
- Continued execution of strategic priorities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$1,003 |
2024 Full Year Media Release
|
26 Feb 2025 8:10AM |
$7.870 |
$7.390 |
fallen by
6.10%
|
|
SIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $305.8 million, up 22% on CY 2023
- Operating EBITDA of $118.7 million, up 18% on pcp
- EBITDA margin was 39%
- NPATA of $72.4 million, up 15% on pcp
- 20% increase in novated leasing settlements
- Electric Vehicles accounted for 44% of CY 2024 new car lease orders
- Strong operating cash flow at 108% of NPATA
- Final ordinary dividend of 20 cents per share and special dividend of 11 cents declared
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$1,003 |
Dividend/Distribution - SIQ
|
26 Feb 2025 8:10AM |
$7.870 |
$7.390 |
fallen by
6.10%
|
|
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$1,003 |
2024 Sustainability Report
|
26 Feb 2025 8:09AM |
$7.870 |
$7.390 |
fallen by
6.10%
|
|
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$1,003 |
Appendix 4E and 2024 Annual Report
|
26 Feb 2025 8:09AM |
$7.870 |
$7.390 |
fallen by
6.10%
|
|
SIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- 2024 revenue increased by 21.6% to $305,842,000.
- Profit after tax rose by 22.1% to $75,599,000.
- Smartgroup focuses on employee benefits and fleet management services.
- Successful digital initiatives have improved operational efficiency.
- The company has long-term contracts in key sectors like government and healthcare.
- Leadership changes include John Prendiville as Chairman and Scott Wharton as CEO.
- Commitment to sustainability and customer retention highlighted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$46 |
2025 Half-Year Financial Report
|
26 Feb 2025 8:09AM |
$0.099 |
$0.069 |
fallen by
30.30%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$309 |
Dividend/Distribution - COG
|
26 Feb 2025 8:09AM |
$1.020 |
$1.530 |
risen by
50%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$309 |
Appendix 4D & Half Year Financial Report
|
26 Feb 2025 8:09AM |
$1.020 |
$1.530 |
risen by
50%
|
|
COG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations increased by 7% to $252.98 million.
- Net profit from continuing operations decreased by 9% to $13.60 million.
- Earnings per share decreased to 4.28 cents.
- Net assets were valued at $200.56 million.
- COG aims for growth through strategic acquisitions in the asset finance sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$855 |
Appendix 4D and Half Year Accounts
|
26 Feb 2025 8:09AM |
$3.620 |
$3.150 |
fallen by
12.98%
|
|
KLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 9.1% to $1,071.8 million.
- Underlying EBITDA rose by 1.3% to $132.2 million.
- Underlying net profit after tax decreased by 7.9% to $39.7 million.
- The company operates Australia's largest zero-emission bus fleet.
- Kelsian paid a fully franked interim dividend of 8.0 cents per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oneview Healthcare Plc (ONE) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$214 |
Notification of cessation of securities - ONE
|
26 Feb 2025 8:09AM |
$0.340 |
$0.280 |
fallen by
17.65%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
